About 9 results found for searched term "c-Kit-IN-3" (0.117 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M57861 | c-Kit-IN-3 | Others |
| c-Kit-IN-3 | ||
| M1656 | Tivozanib (AV-951) | VEGFR/PDGFR |
| KRN951; Tivozanib | ||
| AV-951 (Tivozanib) is a potent VEGFR-1, 2 and 3, c-Kit and PDGFR inhibitor with IC50 of 0.21, 0.16, 0.24, 1.63 and 1.72 nM respectively. | ||
| M5066 | N-Desethyl Sunitinib | Metabolite/Endogenous Metabolite |
| SU11662 | ||
| N-desethyl sunitinib is a major and pharmacologically active metabolite of sunitinib, which is potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor (Ki values are 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT respectively). | ||
| M20715 | CS-2660 (JNJ-38158471) | VEGFR/PDGFR |
| CS-2660 (JNJ-38158471) is a well tolerated, orally available, highly selective VEGFR-2 inhibitor with IC50 of 40 nM. CS-2660 (JNJ-38158471) also inhibits closely related tyrosine kinases such as Ret and Kit with IC50 of 180 nM and 500 nM，while it has no significant activity (>1 microM) against VEGFR-1 and VEGFR-3. | ||
| M22464 | M4205 | c-Kit |
| M-4205; IDRX-42 | ||
| M4205 is a c-KIT inhibitor, with an IC50 of 10 nM for c-KIT V654A. M4205 has high activity on c-KIT mutations in exon 11, 13, 17. | ||
| M27604 | c-Kit-IN-5-1 | c-Kit |
| c-Kit-IN-5 is potent inhibitor of c-Kit, with IC50s of 22 nM and 16 nM in kinase assay and cell assay, respectively. c-Kit-IN-5 shows more than 200-fold selectivity for c-Kit over KDR, p38, Lck, and Src. c-Kit-IN-5 also exhibits desirable pharmacokinetic properties. | ||
| M28074 | HG-7-85-01 | Src-bcr-Abl |
| HG-7-85-01 is a type II ATP competitive inhibitor of wild-type and gatekeeper mutations forms of Bcr-Abl, PDGFRα, Kit, and Src kinases. HG-7-85-01 inhibits T315I mutant Bcr-Abl kinase, KDR and RET with IC50s of 3 nM, 20 nM and 30 nM, and is only weak or no inhibition of other kinases (IC50>2 μM). HG-7-85-01 inhibits the cell proliferation, which is mediated by the induction of apoptosis, and inhibition of cell-cycle progression. | ||
| M29174 | CHMFL-ABL/KIT-155 | Src-bcr-Abl |
| CHMFL-ABL-KIT-155 | ||
| CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC50s of 46 nM and 75 nM, respectively), and it also presents significant inhibitory activities to BLK (IC50=81 nM), CSF1R (IC50=227 nM), DDR1 (IC50=116 nM), DDR2 (IC50=325 nM), LCK (IC50=12 nM) and PDGFRβ (IC50=80 nM) kinases. | ||
| M45307 | Multi-kinase-IN-6 | Casein Kinase |
| Multi-kinase-IN-6 is a multikinase inhibitor that shows good enzyme inhibitory activity against TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1 and CDK2. In addition, Multi-kinase-IN-6 also showed antiproliferative activity against MCF7, HCT116 and EKVX, with IC50 values of 3.36 μM, 1.40 μM and 3.49 μM, respectively, and showed good apoptotic activity in MCF7 and HCT116 cells with cell-cycle arrest in G1/S and G1 phases. phase, with good apoptosis effect. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
